Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
When Will Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Breakeven?
Leerink Partners Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $5
Leerink Partners analyst Roanna Ruiz maintains $Xeris Pharmaceuticals(XERS.US)$ with a buy rating, and sets the target price at $5.According to TipRanks data, the analyst has a success rate of 32.4%
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Craig-Hallum analyst Chase Knickerbocker maintains $Xeris Pharmaceuticals(XERS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.8% and a total average return of
Xeris Pharmaceuticals (XERS) Gets a Buy From Craig-Hallum
Xeris Biopharma Appoints John Shannon as CEO